Chemohormonal Therapy vs. Hormonal Therapy for Hormone-sensitive mPrCa
Chemohormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
Christopher Sweeney, MD presents results of the CHAARTED trial, which looked at the effects of adding docetaxel chemotherapy at the time of commencement of androgen deprivation therapy (ADT) in men with mCRPC.
Christopher Sweeney, MD
Dana-Farber Cancer Institute
SEE RELATED CONTENT
Christopher J. Sweeney, received his medical degree from the University of Adelaide, South Australia in 1992, and completed an internship at the Royal Adelaide Hospital. From 1994 to 1997, Dr. Sweeney was an Internal Medicine resident at Gundersen Lutheran Medical Center, La Crosse, Wisconsin, and from 1997 to 2000, he was a Fellow in Hematology/Oncology at Indiana University Medical Center. Dr. Sweeney is certified by the American Board of Internal Medicine in Medical Oncology. He has held faculty appointments at Indiana University and Royal Adelaide Hospital.
In 2009 he joined the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and in 2012 became Clinical Director. He is an Associate Professor at Harvard Medical School. He is a member of the American Society of Clinical Oncology, Eastern Cooperative Oncology Group, Alliance and American Association for Cancer Research. Dr. Sweeney has served as the Associate Director for Clinical Research for the NCI-designated, Indiana University Simon Cancer Center and Co-Leader of the Experimental Developmental Therapeutics Program, and Chairman of the Hoosier Oncology Group from 2005 to 2007.
Dr. Sweeney has served on the Program Committee and the Cancer Education Committee of the American Society of Clinical Oncology and has been on the Editorial Board for ASCOs “Journal of Clinical Oncology”. He has received peer reviewed funding from the National Institutes of Health and the Department of Defense, Lance Armstrong Foundation, and PhRMA. He has also been honored to receive philanthropic support from the Shawmut Design and Construction company. He has also served on the Scientific Advisory Board of biotech companies both in Australia and USA. His research has focused on drug development and identify markers of response to therapy with a focus on prostate cancer.